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Proteins as Cross-Protective Influenza VaccineWei Dong, Yoshita Bhide, Sonny Marsman, Marijke Holtrop, Tjarko Meijerhof,
Jacqueline de Vries-Idema, Aalzen de Haan, and Anke Huckriede*Induction of CD8þ cytotoxic T cells (CTLs) to conserved internal influenza antigens,
such as nucleoprotein (NP), is a promising strategy for the development of cross-
protective influenza vaccines. However, influenza NP protein alone cannot induce
CTL immunity due to its low capacity to activate antigen-presenting cells (APCs)
and get access to the MHC class I antigen processing pathway. To facilitate the
generation of NP-specific CTL immunity the authors develop a novel influenza
vaccine consisting of virosomes with the Toll-like receptor 4 (TLR4) ligand
monophosphoryl lipid A (MPLA) and the metal-ion-chelating lipid DOGS-NTA-Ni
incorporated in the membrane. In vitro, virosomes with incorporated MPLA induce
stronger activation of APCs than unadjuvanted virosomes. Virosomes modified
with DOGS-NTA-Ni show high conjugation efficacy for his-tagged proteins and
facilitate efficient uptake of conjugated proteins by APCs. Immunization of mice
with MPLA-adjuvanted virosomes with attached NP results in priming of NP-
specific CTLs while MPLA-adjuvanted virosomes with admixed NP are inefficient in
priming CTLs. Both vaccines induce equally high titers of NP-specific antibodies.
When challenged with heterosubtypic influenza virus, mice immunized with
virosomes with attached or admixed NP are protected from severe weight loss.
Yet, unexpectedly, they show more weight loss and more severe disease symptoms
than mice immunized with MPLA-virosomes without NP. Taken together, these
results indicate that virosomes with conjugated antigen and adjuvant incorporated
in the membrane are effective in priming of CTLs and eliciting antigen-specific
antibody responses in vivo. However, for protection from influenza infection NP-
specific immunity appears not to be advantageous.W. Dong, Y. Bhide, S. Marsman, M. Holtrop, T. Meijerhof, J. de
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Inﬂuenza A virus infections cause consider-
able mortality and morbidity to the human
population during seasonal epidemics and
occasional pandemics. Depending on the
sequence of the hemagglutinin (HA) and
neuraminidase (NA) carried on the surface of
the virus particle, inﬂuenza A virus can be
divided into various subtypes. During sea-
sonal epidemics, caused by H1N1 or H3N2
viruses,5–10%of theworldwidepopulationis
infected, resulting in 3–5 million people
suffering from severe illness and up to
500000 deaths per year.[1,2] During the last
inﬂuenza pandemic caused by H1N1pdm
virus in 2009, it was estimated that the overall
cumulative incidence of infection was 24%
and asmany as 284500 people succumbed to
H1N1pdm-related illness.[3,4] Additionally,
avian inﬂuenza viruses, such as H7N9 and
H5N1, are also reported to cause high
mortality in humans yet do not transmit
efﬁciently from human to human.[5,6]
Vaccination is the primary strategy to
prevent inﬂuenza virus infection. Currently,
licensed inﬂuenza vaccines include whole
inactivated inﬂuenza virus, split virus, sub-
unit, and virosomal vaccines.[7] These vac-
cinesmainly induce inﬂuenza strain-speciﬁcantibodieswhichcanbind to the virus surfaceproteins,HAandNA.
However, due to thehighvariability ofHAandNAthevaccinesneedy
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strains but still they are unable to protect against newly emerging
strains. An inﬂuenza vaccine which can induce cross-protective
immune responses to diverse inﬂuenza virus strains is, therefore,
urgently needed.
CD8þ cytotoxic T cells (CTLs) to conserved inﬂuenza virus
antigens, such as nucleoprotein (NP), are required for optimal
cross-protective immune responses.[8,9,10] Inﬂuenza virus-spe-
ciﬁc CTLs can clear virus-infected cells and subsequently stop
virus replication and virus spread in the body. Therefore,
inducing CTLs to conserved inﬂuenza virus protein is an
attractive approach for eliciting cross-protective immunity
against various inﬂuenza virus strains.
Antigen-presenting cells (APCs) play a key role in priming CTL
responses.[11] Priming of CTLs by non-replicating vaccines and by
pathogens which do not infect APCs directly, relies on a
mechanism called cross-presentation.[12] Cross-presentation
requires uptake by APCs of sufﬁcient amounts of antigen which
can enter theMHCclass I processing and presentation pathway as
well as proper activation of the APCs to trigger physiological
processes involved in cross-presentation.[11,12] A conserved
protein, such as NP, alone is thus ineffective in inducing CD8þ
T cell immunity due to its low capacity to reach the MHC class I
processing pathway and its inability to activate APCs.[13,14]
Uptake of antigen by APCs can be facilitated by use of a delivery
system. Inﬂuenza virosomes are reconstituted viral membrane
envelopes which consist only of the membrane lipids and the
surface proteins of inﬂuenza virus. Virosomes retain the cell
bindingandmembrane fusionabilitiesof the livevirus.Due to these
properties, virosomes can deliver encapsulated cargo to the cytosol
of APCs and subsequently induceCTL responses.[15] However, only
limited amounts of protein can be encapsulated into virosomes
when adding the protein during virosome reconstitution.[16]
Moreover, due to a lack of adjuvant virosomes are inefﬁcient in
activating APCs and thus in triggering cross-presentation, which
limits the induction of CTL immunity.[17] Increasing the amount of
antigen associated with the virosomes and adding an adjuvant to
enable APC activation and thus improve cross-presentation may
signiﬁcantly enhance the induction of CTLs.
In this study, we used two strategies to modify inﬂuenza
virosomes to overcome the above-mentioned drawbacks. Firstly, a
nickel-chelating lipid was incorporated into the lipid bilayer of
inﬂuenza virosomes. The presence of nickel-carrying lipids
facilitates binding of large amounts of histidine (his)-tagged protein
to the surface of lipid-based carriers.[18] Secondly, monophosphoryl
lipid A (MPLA), a Toll-like receptor 4 (TLR4) ligand, was
incorporated into the virosomal membrane.[19] TLR 4 engagement
on APCs not only results in activation of the cells but can also
promote cross-presentation.[20,21] Thesenovel “all-in-one” inﬂuenza
virosome particles, with his-tagged NP attached to the membrane
and incorporated MPLA, were tested in vitro and in vivo.2. Experimental Section
2.1. Material
Monophosphoryl lipid A (MPLA), 1,2-dihexanoylan-glyero-3-
phosphocholine (DCPC), the nickel salt of 1,2-dioleoyl-sn-Biotechnol. J. 2018, 13, 1700645 1700645 (2 of 9) © 2018 Theglycero-3-{[N-(5-amino-1-carboxypentyl) iminodiacetic acid] suc-
cinyl} (DOGS-NTA-Ni) and the ammonium salt of 1,2-dioleoyl-
sn-glycero-3-[(N-(5-amino-1-carboxypentyl)iminodiacetic acid)
succinyl] (DOGS-NTA) were purchased from Avanti Polar Lipids
(Alabaster, AL).2.2. Expression and Purification of His-Tagged Recombinant
Proteins
Recombinant pET32a-NP and pET32a-EGFP plasmids were
generated by inserting the NP gene derived from A/Hongkong/
2/1968 (H3N2, called HK68 in the following) or the gene
encoding enhanced green ﬂuorescent protein (EGFP) into
vector pET32a (Merck Millipore, Germany). The recombinant
plasmids were transfected into competent Escherichia coli
AD494 (Merck Millipore) and the cells were cultured in LB
broth supplemented with ampicillin and kanamycin. When an
OD600 of 0.8 was reached, 0.5mM isopropyl β-D-1-thiogalacto-
pyranoside (IPTG) was added to induce the expression of the
his-tagged proteins. His-tagged proteins were puriﬁed by Ni-
chelate afﬁnity resin (Merck Millipore). Brieﬂy, BugBuster
protein extraction reagent (Merck Millipore) with 6M urea was
used for lysis of transfected E. coli. Ni-NTA resin was
equilibrated with binding buffer (0.1M HEPES, 0.5M NaCl)
and then incubated with E. coli lysate at 4 C overnight with
rotation. The resin column was then washed twice with
washing buffer (0.1M HEPES, 0.5M NaCl, 20mM imidazole).
Then, 1.8ml of elution buffer (0.1M HEPES, 0.5M NaCl,
400mM imidazole) with 6M urea were added and incubated
with the column at room temperature for 10min. After that, the
eluted samples were collected and the presence of his-tagged
protein was analyzed by SDS–PAGE on 10% gel stained with
Coomassie blue. The purity of the proteins was more than 90%
(Figure S1, Supporting Information). An endotoxin removal
resin column (Thermo Fisher, Germany) was used to remove
residual endotoxin from these proteins. Determination of
residual endotoxin revealed that 99% of endotoxin was removed
by this procedure. After that, proteins were dialyzed against
HEPES-buffered saline (HBS; 5mM HEPES, 3mM EDTA,
0.15M NaCl, pH 7.4) to remove imidazole and urea. The
concentrations of the proteins were determined by micro-
Lowry.[22] The puriﬁed proteins were stored at 4 C until use.2.3. Influenza Virus and Cell Culture
A/New Caledonia/20/1999 (H1N1, NC99 in the following) was
kindly provided by Solvay Biologicals (Weesp, The Netherlands).
A/HongKong/2/1968 (H3N2, HK68 in the following) virus for
mouse challenge was kindly provided by Guus F. Rimmelzwaan
(Erasmus MC, Rotterdam, The Netherlands). NC99 was
inactivated by overnight incubation with 0.1% β-propiolactone
(Thermo Fisher Scientiﬁc, Geel, Belgium) in citrate buffer
(125mM sodiumcitrate, 150mM sodium chloride, pH 8.2) at
4 C with rotation.
RAW-BlueTM cells were purchased from InvivoGen (USA) and
maintained according to the manufacturer’s protocol.Authors. Biotechnology Journal Published by Wiley-VCHVerlag GmbH & Co. KGaA.
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Inﬂuenza virosomes were prepared from inactivated NC99
inﬂuenza virus according to the protocol published before with
some modiﬁcation.[23,24] Brieﬂy, DOGS-NTA-Ni or DOGS-NTA,
dissolved in chloroform, were mixed with MPLA, dissolved in
ethanol, at a ratio of 100 nmol DOGS:100 μg MPLA. The
solvents were dried under a stream of nitrogen and the lipid
ﬁlm was further dried under vacuum in a SpeedVac centrifuge
for 3 h. Meanwhile, inactivated inﬂuenza virus was disrupted
with 0.1mM DCPC in HBS and the nucleocapsid was removed
by ultracentrifugation. The supernatant containing the viral
surface proteins and membrane lipids (1 μmol phospholipids)
was collected and was incubated with the dried ﬁlm of lipid
(containing MPLA and DOGS lipids) at room temperature for
half an hour on ice. Tubes were inverted every 5min to dissolve
the lipid mixtures. Modiﬁed virosomes were reconstituted by
removal of DCPC by dialysis against HBS buffer overnight with
Slide-A-Lyzer Mini Dialysis Devices (10K MWCO) (Thermo
Fisher, Germany). The buffer was changed on the second day
for another 4 h of dialysis. Non-incorporated material was
removed from the virosomes on a discontinuous sucrose
gradient (10–30–50%, w/v). Subsequently, the sucrose in the
virosomes was removed by dialysis against HBS. The
concentration of virosomal proteins was determined by
micro-Lowry. These modiﬁed virosomes were kept at 4 C until
further use.
The composition of and the nomenclature for the different
virosome preparations used in the following are described in
Table S1, Supporting Information.2.5. Characterization of MPLA Incorporation
To evaluate the incorporation of MPLA into the virosomes, the
mouse macrophage reporter cell line RAW-BlueTM was used.
Lipid-modiﬁed virosomes were incubated with RAW-BlueTM
cells (105/well) in a 96-well plate overnight at 37 C in a 5% CO2
incubator. QUANTI-Blue (Invivogen, USA) was added to 40 μl of
the supernatant. After 10min incubation at room temperature,
the absorbance at 650 nm was measured in an ELISA reader. E.
coli lipopolysaccharide (LPS; Sigma–Aldrich Chemie B.V
Zwijndrecht, the Netherlands) and CpG oligodeoxynucleotides
1826 (CpG ODN; Eurogentec, Maastricht, the Netherlands) were
used as positive controls.2.6. Conjugation of His-Tagged Protein to Modified
Virosomes
Plain virosomes without (VNi) and with DOGS-NTA-Ni (VNiþ)
and virosomes with MPLA without (M/VNi) and with
DOGS-NTA-Ni (M/VNiþ) (100 μg virosomal protein) were
incubated with his-tagged EGFP (100–800 μg) at room tempera-
ture for 30min with rotation. The conjugation of his-tagged
EGFP with virosomes was analyzed by equilibrium density
gradient centrifugation on a 10–30–50% sucrose gradient. The
gradient was centrifuged in a TLS55 rotor at 35 000 rpm for
90min. Subsequently, fractions of the gradient were analyzed forBiotechnol. J. 2018, 13, 1700645 1700645 (3 of 9) © 2018 Theprotein and ﬂuorescence by ELISA reader (BioTech, USA). The
fractions containing virosomes with attached his-tagged EGFP
were collected and the sucrose was removed as before. The
puriﬁed virosomes with attached his-tagged EGFP (VNiþ-EGFP,
M/VNiþ-EGFP in the following) and the mixture of virosomes
with unattached his-tagged EGFP (VNiþEGFP, M/VNiþEGFP
in the following) were quantiﬁed by micro-Lowry and kept at
4 C until use.
The binding of his-tagged NP to modiﬁed virosomes (100 μg
virosomal proteinþ 100–400 μg NP) was performed as above.
The puriﬁed virosomes with attached his-tagged NP (VNiþ-NP,
M/VNiþ-NP in the following) and the mixture of virosomes with
unattached his-tagged NP (VNiþNP, VNi/MþNP in the
following) were quantiﬁed by micro-Lowry and kept at 4 C until
use.2.7. Uptake of Free and Virosome-Conjugated EGFP by APCs
RAW-BlueTM cells were used to determine the uptake of his-
tagged proteins as follows. VNiþ-EGFP was prepared by
incubating his-tagged EGFP (0 μg, 1.25 μg, 2.5μg, or 5 μg) with
VNiþ (1 μg) as above. Free his-tagged EGFP (0 μg, 1.25 μg, 2.5μg,
or 5 μg) or VNiþ-EGFP were then incubated with RAW-Blue
TM
cells (5 105/tube) at 37 C for 1 h. Cells were washed with FACS
buffer (PBS with 2% FBS) 3 times and analyzed on a FACS
CaliburTM BD II ﬂow cytometer. Data were analyzed by Kaluza1
Flow Cytometry Analysis Software.2.8. Vaccination
Animal experiments were performed according to the
guidelines provided by the Dutch Animal Protection Act
and the protocols were approved by the Animal Ethics
Committee (DEC) of the University Medical Center Gro-
ningen (UMCG).
Six to eight weeks old female C57BL/6JOlaHsd mice (Envigo,
The Netherlands) were separated into 5 groups of 12 mice. Mice
were intramuscularly immunized with 25 μl vaccine in each hind
leg on day 0 and day 21 under isoﬂurane anesthesia. Vaccines
included virosomes with MPLA (M/V; 2.5 μg virosomal protein),
M/VNiþ-NP (2.5 μg virosomal protein with 10 μg his-NP), M/
VNiþNP (2.5 μg virosomal protein with 10 μg his-NP) or free
NP protein alone (10 μg his-NP). PBS served as negative control.
On day 28, mice were challenged by intranasal administration of
103 TCID50 of HK68 virus in 40 μl of HBS under isoﬂurane
anesthesia. On day 31, 6 mice in each group were sacriﬁced and
serum samples, lung tissues, and spleen tissues were collected
for further experiments. The remaining mice were monitored
daily for 14 days to assess disease symptoms and potential
recovery.2.9. Elispot Assays
Inﬂuenza NP-speciﬁc IFN-γ producing cells in spleen were
determined using an Elispot kit (eBioscience, The Netherlands)
according to the manufacturer’s protocol. Brieﬂy, 96-wellAuthors. Biotechnology Journal Published by Wiley-VCHVerlag GmbH & Co. KGaA.
www.advancedsciencenews.com www.biotechnology-journal.comMultiscreen PVDF ﬁlter plates (Millipore, Billerica, MA) were
activated with 50 μl of 70% ethanol for 2min and then washed
three times with PBS. Anti-mouse IFN-γ capture antibodies
were added to the plates and incubated at 4 C overnight. On the
next day, the plates were washed 3 times and blocked with
DMEM medium with 10% FBS for 2 h at room temperature.
Subsequently, splenocytes were added (5 105/well) with or
without 5 μgml1 of NP peptide (ASNENMDAM; a H2-Db-
restricted epitope of NP of H3N2 virus) and then incubated at
37 C in IMDM complete medium overnight. After overnight
incubation, plates were washed 5 times and IFN-γ producing
cells were detected by using horseradish peroxidase (HRP)
conjugated anti-mouse IFN-γ antibodies. Spots were detected by
using an ACE staining kit (Sigma, Sigma–Aldrich, USA) and
counted by AID Elispot reader (Autoimmune Diagnostika
GmbH, Strassberg, Germany). The number of antigen-speciﬁc
IFN-γ producing cells was calculated by subtracting the number
of spots detected in the unstimulated samples from the number
in stimulated samples.2.10. Virus Titration in Lung Tissue
Lung tissue collected at day 3 post challenge was homogenized in
1ml of PBS and centrifuged at 1200 rpm for 10min. Super-
natants were collected, aliquoted, and stored at80 C until use.
Lung virus titers were determined by infection of MDCK cells in
96-well plates with serial dilutions of the lung supernatants as
described before.[25]2.11. ELISA and Microneutralization Assay
Serum antibodies against the surface proteins of HK68 virus and
antibody against NP protein were detected by ELISA as
previously published.[24] Brieﬂy, 0.3 μg of HK68 subunit vaccine
prepared as before or 0.3μg of his-tagged NP protein was coated
on 96-well plates overnight in 100 μl of coating buffer (0.05M
carbonate bicarbonate, pH 9.6–9.8). Then, plates were blocked
with 200 μl of 2.5% milk powder solution in coating buffer for
45min at 37 C. A series of twofold diluted serum samples was
then added to the plate and incubated for 1.5 h for 37 C.
Subsequently, horseradish peroxidase (HRP)-conjugated goat
anti-mouse IgG antibody was added and incubated for 1 h at
37 C. O-phenylene-diamine(OPD) was used as a substrate to
react with HRP. The reaction was stopped by adding 50 μl of 2M
H2SO4. The plates were then read at 492 nm. IgG titers were
calculated as the log value of the reciprocal of the dilution of
serum sample corresponding to an OD492nm of 0.2. Micro-
neutralization (MN) assay was performed as described
previously.[25]Figure 1. Bioactivityofmodifiedvirosomes invitro.RAW-Blue cellswereco-
culturedwith the indicated virosomepreparations orwith TLR ligands. After
overnight incubation, SEAP activity in the supernatant was detected by
QUANTI-Blue. Representative of two independent experiments. Data
represent mean O.D. values SEM. p< 0.0001, Mann–Whitney U-test.2.12. Statistics
Differences between read-outs of two different vaccination
groups were analyzed using Mann–WhitneyU-test. p< 0.05 was
considered as signiﬁcantly different.Biotechnol. J. 2018, 13, 1700645 1700645 (4 of 9) © 2018 The3. Results
3.1. Incorporation of MPLA Enhances the APC-Activating
Capacity of Modified Virosomes
MPLA has been tested as adjuvant because it can activate APCs
through engagement with TLR4 expressed on the cell surface.
We ﬁrst determined whether the modiﬁed inﬂuenza virosomal
vaccines can activate APCs utilizing the RAW-BlueTM cell line
which stably expresses all TLRs (except TLR5) and contains a
reporter gene, secreted embryonic alkaline phosphatase (SEAP),
inducible by NF-кb and AP-1. RAW-BlueTM cells were cultured
with either inﬂuenza virosomes only (V), virosomes with
incorporated MPLA (M/V), virosomes with incorporated
DOGs-NTA-Ni (VNiþ), or the TLR agonists CpG or LPS. As
shown in Figure 1, the TLR ligands LPS and CpG activated the
NF-кb signaling pathway resulting in the production of SEAP.
M/V also strongly activated the RAW-BlueTM cells. In contrast,
virosomes without MPLA (V, VNiþ) failed to activate NF-кb
signaling. These results demonstrate that MPLA was success-
fully incorporated into virosomes enabling the virosomes to
activate APCs in vitro. Moreover, VNiþ did not activate RAW-
BlueTM cells indicating that presence of DOGs lipids alone is
insufﬁcient for activation of APCs.3.2. His-Tagged Protein is Conjugated to Modified
Virosomes
To assess the conjugation of his-tagged protein to modiﬁed
virosomes we incubated his-tagged EGFP with different types of
modiﬁed virosomes. The presence of the histidine residues
provides a tag that can bind with Niþ chelating lipid. After mixing
his-tagged EGFP with modiﬁed inﬂuenza virosomes, including
VNi, VNiþ, and M/VNiþ, the conjugation of his-tagged protein to
these modiﬁed virosomes was determined by sucrose density
gradient centrifugation. When incubating his-tagged EGFP withAuthors. Biotechnology Journal Published by Wiley-VCHVerlag GmbH & Co. KGaA.
Figure 2. Conjugation ability and binding capacity of modified virosomes for his-tagged
EGFP. A–C) Modified virosomes (100 μg), including VNi (A), VNiþ (B), and M/VNiþ (C),
were mixed with his-tagged EGFP (100 μg) at room temperature for 30min.
Subsequently, free his-tagged EGFP protein was separated from conjugated EGFP on
a 10–30–50% sucrose gradient by ultracentrifugation. D–F)M/VNiþ (100 μg) were mixed
with various amounts (D: 200 μg, E: 400 μg, F: 800 μg) of his-tagged EGFP at room
temperature for 30min. Subsequently, free his-tagged EGFP protein was separated from
conjugated EGFP on a 10–30–50% sucrose gradient by ultracentrifugation. The
absorbance at 280 nm and the fluorescence of each fraction were determined by ELISA
reader as described in Section 2. The solid line represents the absorbance of protein in
each fraction at 280 nm while the dashed line represents the fluorescence of his-tagged
EGFP. Data representative of three independent experiments.
Figure 3. Uptake of free EGFP or conjugated EGFP by APCs in vitro. RAW-BlueTM cells
were incubated with various amounts of free EGFP (A) or modified virosomes (M/VNiþ)
with conjugated EGFP (B) at 37 C for 1 h and then the uptake of EGFP was analyzed by
flow cytometry.
www.advancedsciencenews.com www.biotechnology-journal.comvirosomes without Ni (VNi), the ﬂuorescence of his-
tagged EGFP was mainly detected in the top fraction
while virosomal protein was mainly detected in the
middle fraction of the gradient (Figure 2A). In
contrast, virosomal and ﬂuorescent protein migrated
to the same fractions of the gradient when his-tagged
EGFP was incubated with VNiþ (Figure 2B). This
indicates that the presence of Niþ is crucial for the
conjugation of his-tagged protein to virosomes.
Moreover, as shown in Figure 2C, after incubating
his-tagged EGFP with M/VNiþ, protein and ﬂuores-
cence signal also migrated together to the same
fractions of the gradient, which demonstrates that
incorporationofMPLAintovirosomedidnot interfere
with the conjugation of his-tagged protein to
membrane-incorporated DOGS-NTA-Ni.
To determine the binding capacity of M/VNiþ for
his-tagged protein, a ﬁxed amount of M/VNiþBiotechnol. J. 2018, 13, 1700645 1700645 (5 of 9) © 2018 The Authors. Biotecvirosomes was incubated with different amounts of
his-tagged EGFP as indicated in Section 2. The
conjugation of his-tagged protein to the virosomes
was then analyzed by sucrose density gradient
centrifugation. Protein and ﬂuorescent signals from
different fractions of the sucrose gradient showed that
all the his-tagged EGFP co-migrated with the
virosomal protein to the same fraction of the sucrose
gradient when the ratio of virosomal protein to his-
tagged EGFP was 1:2 or 1:4 (Figure 2D and E). In
contrast, a strong ﬂuorescent signal was found in the
top fractions of the gradient when the ratio of
virosomal protein:EGFP was 1:8, indicating that only
part of thehis-taggedEGFPwas conjugated toM/VNiþ
under those conditions (Figure 2F). M/VNiþ showed
similar conjugation capacity for his-tagged NP
protein. At virosomal protein:NP ratios of 1:2 and
1:3 all NPwas bound to the virosomes but at a ratio of
1:5 NP started to appear in the top fraction of the
gradient (Figure S2, Supporting Information). Taken
together, M/VNiþ showed high conjugation efﬁcacy
for his-tagged proteins.3.3. Modified Virosomes Facilitate the Uptake of
Conjugated His-Tagged Protein by APCs
We hypothesized that conjugation of a protein to
inﬂuenza virosomes will facilitate its uptake by
APCs. The uptake of his-tagged protein by APCs was
determined by incubating M/VNiþ-EGFP or free
EGFP protein with RAW-BlueTM cells and quantiﬁ-
cation of internalized EGFP by ﬂow cytometry. As
shown in Figure 3, after 1 h incubation, free EGFP
was not internalized efﬁciently by RAW-BlueTM
cells. However, EGFP conjugated to virosomes was
readily taken up by RAW-BlueTM cells, as indicated
by amarked increase inmean ﬂuorescence intensity.
Moreover, higher amounts of the M/VNiþ-EGFPhnology Journal Published by Wiley-VCHVerlag GmbH & Co. KGaA.
www.advancedsciencenews.com www.biotechnology-journal.comresulted in more uptake by APCs. These results indicate that
conjugation of his-tagged protein to virosomes enhances antigen
uptake by APCs.3.4. Virosomes with Associated NP Induce Cytotoxic T
Lymphocytes and NP-Specific Antibodies
We next evaluated the immunogenic properties of the modiﬁed
virosomes in vivo. We hypothesized that attachment of NP and
incorporation of MPLA into virosome would facilitate the cross-
presentation of NP thereby allowing induction of NP-speciﬁc
CTLs which could aid in protection from virus challenge.
Moreover, immunization with modiﬁed virosomes with NP was
expected to induce NP-speciﬁc antibodies.
Modiﬁed virosomes were prepared from NC99 (H1N1) while
NP protein was derived fromHK68 (H3N2). C57BL/6 mice were
primed and boosted with either M/VNiþNP, M/VNiþ-NP, free
NP mixed with MPLA or M/V on day 0 and day 21. Control
animals received PBS.
To identify NP-speciﬁc IFN-γ producing cells against HK68
NP, the NP366–374 epitope (ASNENMDAM) present in HK68 NP
but absent from NC99 virus was used to stimulate mouse
splenocytes. As indicated in Figure 4A, only M/VNiþ-NP induced
signiﬁcant numbers of NP-speciﬁc IFN-γ producing Tcells while
the number of NP-speciﬁc CTLs found after immunization with
M/VNi-þNP, M/VNiþ, or free NP protein mixed with MPLA was
not signiﬁcantly different from the number observed in PBS
control mice.
To detect NP-speciﬁc antibody responses, mouse serum
samples taken 3 days post challenge were analyzed by ELISA. As
shown in Figure 4B, NP-speciﬁc antibody titers in each of the
NP-vaccinated groups (M/VNi-þNP, M/VNiþ-NP, and
NPþMPLA), were signiﬁcantly higher than in the PBS control
group. Moreover, M/VNi-þNP and M/VNiþ-NP vaccination
induced higher levels of NP-speciﬁc antibodies compared to
vaccination with MPLA-adjuvanted free NP.Figure 4. Immunogenicity of modified virosomes in vivo. C57BL/6 m
immunized either with the mixture of free NP with virosomes (M/VNi-þ
conjugated virosomes (M/VNiþ-NP), MPLA conjugated virosomes without
the mixture of NP with MPLA, or PBS on day 0 and day 21. On day 28,
challenged intranasally with 103 TCID50 of HK68. On 3 days post challenge (da
specific CD8 T cell immunity in splenocytes was determined ex vivo by ELISPO
specific IgG in serum was analyzed by ELISA (B). Data represent mean SE
p< 0.05, p< 0.005. NS, not significant.
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Against Virus Infection
Next, the protective potential of the modiﬁed virosome vaccines
against heterosubtypic virus infection was determined. Mice
were vaccinated twice as described above with modiﬁed NC99
(H1N1)-derived virosomes with admixed or attached HK68 NP,
with HK68 NPþMPLA or with plain virosomes and were
subsequently challenged with a lethal dose of HK68 (H3N2)
virus.
After virus challenge, ﬁve out of six mice in the PBS control
group developed severe symptoms and lost more than 20%
weight (humane endpoint) necessitating euthanasia on day 7 or
8 post infection (Figure 5A and B). Mice that were immunized
with the mixture of NP protein and MPLA showed more rapid
weight loss than mice in the PBS control group, but three mice
in this group started to recover from day 5 post infection
onwards. In the M/VNi-þNP vaccinated group, four out of six
mice showed rapid weight loss as observed in the NPþMPLA
group. However, these mice started to recover from day 7 post
infection and none of the mice needed to be sacriﬁced. In the M/
VNiþ-NP vaccinated group, one out of six mice had to be
sacriﬁced on day 5 post infection. The other ﬁve mice started to
recover by day 6 or day 7 post infection after a period of moderate
weight loss. Surprisingly, in the M/V vaccinated group, mice
only showed mild weight loss (around 10%) and all mice
recovered quickly.
Determination of virus in lung tissue on day 3 post-infection
revealed almost identical mean virus titers of about 10log 4.5 for
all experimental groups (Figure S3, Supporting Information).
Thus, infection and initial virus growth were not affected by any
of the vaccines.
To explore the possible mechanisms responsible for cross-
protection, sera collected on day 3 post infection from vaccinated
mice were evaluated for antibodies recognizing HK68 virus. As
shown in Figure 6A, MPLA-adjuvanted virosomes derived from
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However, these antibodies were unable to neutralize
HK68 virus particles (Figure 6B).
Taken together, these results indicate that viro-
someswith conjugatedNP could elicit the production
of NP-speciﬁc CTLs and NP-speciﬁc antibodies.
However, NP-speciﬁc immunity was not required
for protection from severe disease symptoms upon
challenge and might even have resulted in immuno-
pathology. Thus, immunization with (NP) virosomes
protected mice against infection with heterosubtypic
HK68 virus by a so far non-identiﬁed mechanism.4. Discussion
In this study, we developed a novel virosomal
inﬂuenza vaccine, aiming to enhance the generation
of inﬂuenza-speciﬁc CD8 T cell responses against
the NP antigen. To this end, MPLA and DOGs-NTA-
Ni lipid were incorporated into the lipid bilayers of
inﬂuenza virosomes. In vitro, M/V strongly activatedhnology Journal Published by Wiley-VCHVerlag GmbH & Co. KGaA.
Figure 5. Weight loss and survival rate after heterosubtypic challenge. Mice (n¼ 6) were vaccinated and challenged as described in Figure 4. After
challenge, mice were monitored daily for weight loss (A) and survival rate (B). Loss of more than 20% of original weight was considered as humane
endpoint.
www.advancedsciencenews.com www.biotechnology-journal.comRAW-BlueTM cells. M/VNiþ exhibited high conjugation ability to
his-tagged EGFP or NP protein and signiﬁcantly enhanced the
uptake of his-tagged protein by APCs. Furthermore, while
virosomes with admixed or conjugated NP induced equal levels
of NP-speciﬁc antibodies, only virosomes with conjugated NP
mounted an NP-speciﬁc CD8 Tcell response. Yet, upon live virus
challenge NP-speciﬁc immunity was not required for protection
since MPLA-adjuvanted virosomes without NP provided the best
protection.
Activation of APCs is a prerequisite for efﬁcient induction of
CTLs by cross-presentation. We found that virosomes with
incorporated MPLA exhibited a stronger ability to activate RAW-
BlueTM cells than plain virosomes. Incorporation of MPLA into
membranous delivery systems has been described before. A
study reported that incorporation of MPLA into virosomes
derived from respiratory syncytial virus (RSV) strongly enhanced
the ability of the virosomes to activate mouse APCs.[19] AnotherFigure 6. Cross-reactive activity of vaccination-induced antibodies against H
Mice (n¼ 6) were vaccinated and challenged as described in Figure 4. On
challenge (day 31), serum antibodies against surface protein (HAþNA) of H
were determined by ELISA (A). Neutralizing antibodies against HK68 v
determined by MN assay (B). Data represent mean SEM. NS, not signific
limit of detection.
Biotechnol. J. 2018, 13, 1700645 1700645 (7 of 9) © 2018 Thestudy reported that incorporation of MPLA into glycoliposomes
not only induced DC maturation, but also enhanceds cross-
presentation of liposome-conjugated tumor antigen to CD8 T
cells.[26] Activation of APCs by membrane-incorporated MPLA
induces the expression of co-stimulatory molecules on the cell
surface and increases cytokine release,[19,26,27] thereby enabling
efﬁcient generation of CD8 T cell immunity.
Next to proper activation of APCs, an important prerequisite
for the induction of CTLs by non-living vaccines is the delivery of
sufﬁcient antigen to the cells. Antigen delivery depends on
adequate loading of antigen in or on the delivery device and
efﬁcient uptake of the loaded delivery device by APCs. We show
that incorporation of DOGS-NTA-Ni into inﬂuenza virosomes
signiﬁcantly enhanced the conjugation of his-tagged EGFP or
NP to virosomes (Figure 2). DOGS-NTA-Ni was earlier shown to
signiﬁcantly increase the association of therapeutically active





Authors. Biotecbiological function of these peptides.[18] Another
study reported by Masek et al. demonstrates that
DOGS-NTA-Ni facilitates the attachment of his-
tagged heat shock protein from Candida albicans
(hsp90-CA) onto liposome.[28] We used DOGS-NTA-
Ni lipid for the ﬁrst time with virosomes which have
a membrane that is densely covered with viral
surface proteins. Nevertheless, presence of DOGS-
NTA-Ni allowed the conjugation of large amounts of
protein to the virosomes indicating that the presence
of the viral surface proteins did not sterically hinder
binding of his-tagged protein. Originally, passive
encapsulation was used to generate protein- or
peptide-carrying inﬂuenza virosomes.[16,17] How-
ever, only approximately 225 ovalbumin (OVA)
molecules could be encapsulated per virosomal
particle using this technique.[16] In contrast, we
estimate that one particle of DOGS-NTA-Ni-con-
taining virosomes could conjugate with about 27 500
molecules of EGFP (equal to 4 μg EGFP/μghnology Journal Published by Wiley-VCHVerlag GmbH & Co. KGaA.
www.advancedsciencenews.com www.biotechnology-journal.comvirosomal protein) or 12 000 molecules of NP (equal to 3 μg NP/
μg virosomal protein). Thus, the incorporation of DOGS-NTA-Ni
facilitated binding of approximately 50 times more NP protein
than could have been achieved by passive encapsulation.
Interaction of antigen and delivery system is important for the
uptake of antigen by APCs and induction of antigen-speciﬁc
CTLs. We demonstrate that the conjugation of his-tagged EGFP
to themembrane ofM/VNiþ signiﬁcantly enhanced the uptake of
the protein by APCs. Our results are in line with those reported
by Soema et al. who show that encapsulation of M1 peptide in
virosomes strongly increased the uptake of the peptide by DCs in
vitro.[17] Another study demonstrates that loading melanoma
tumor antigen gp100 peptide to MPLA-incorporating glycolipo-
somes efﬁciently enhanced the cross-presentation of peptide to
CD8 T cells.[26]
In vivo experiments conﬁrmed our concept that modiﬁed
virosomes combining activation of APCs with efﬁcient antigen
delivery have the potential to effectively activate CD8 T cells.
Indeed, we observed that M/VNiþ-NP induced NP-speciﬁc CD8 T
cells while free NP with MPLA or M/VNi-þNP did not or to a
much lower extent. In contrast, induction of NP-speciﬁc
antibodies was independent of conjugation of NP to virosomes.
Different vaccination strategies have been developed to
generate inﬂuenza-speciﬁc CD8 Tcells. These strategies include
DNAvaccine, viral vector vaccine, peptide vaccine and others (for
review see Ref. [29]). Conserved Tcell epitopes present in peptide
vaccines or expressed by DNA vaccines or viral vector vaccines
could induce inﬂuenza-speciﬁc CD8 Tcells in vivo. Yet, so far the
number of CD8 Tcells that could be induced by these vaccines in
humans was verymoderate (reviewed in Ref. [30]). Accordingly, in
some cases, e.g., the MVA-NPþM1 vaccine and the peptide
vaccine Multimeric-001, the vaccine is not used alone but rather
in combination with or as priming for immunization with
conventional inactivated inﬂuenza vaccine (https://clinicaltrials.
gov/ct2/show/results/NCT03300362).[31] Compared with these
vaccination strategies, M/VNiþ-NP, consisting of virosomes
which present the viral surface proteins and harbor conserved
NP, have the potential to induce not only inﬂuenza-speciﬁc CD8
T cells but also cross-reactive antibodies.
In line with others working on CD8 T cell inducing inﬂuenza
vaccines, we hypothesized that CTL induction by virosomes
would result in mitigation of disease symptoms upon infection
by allowing rapid virus clearance. M/VNiþ-NP immunization
indeed provided a certain level of cross-protective immune
response against heterosubtypic (HK68) virus infection. Yet, a
similar level of cross-protection was achieved with M/VNi-þNP
which did not induce signiﬁcant numbers of NP-speciﬁc CD8 T
cells. This result implies that NP-speciﬁc CD8 T cells were not
crucial for cross-protective immunity afforded by the virosomes.
Moreover, immunization with M/V without NP provided the
best cross-protection against heterosubtypic virus infection,
suggesting that antibodies or T helper cells recognizing HA or
NA were responsible for the observed mitigation of disease
symptoms. No neutralizing antibodies against the challenge
virus were detected, but non-neutralizing antibodies against the
surface proteins (HAþNA) and NP protein were present in the
vaccinated animals. It is possible that these non-neutralizing
antibodies provided cross-protection for example via antibody-
dependent cellular cytotoxicity (ADCC).[32]Biotechnol. J. 2018, 13, 1700645 1700645 (8 of 9) © 2018 TheIt is striking that the presence of NP-speciﬁc immunity
seemed to have a negative rather than a positive effect during the
initial phase of the infection: mice immunized with NP/MPLA
showed a more rapid decline in weight than PBS control mice
and mice immunized with virosomes with admixed or
conjugated NP were less well protected than mice receiving
virosomes without NP. The reason for this phenomenon is not
clear. We consider it unlikely that the observed immunopathol-
ogy was caused by NP-speciﬁc CTLs as CTLs recognizing the
immuno-dominant NP366-374 epitope were not induced by
NPþMPLA and M/VNiþNP. It remains elusive whether NP-
speciﬁc antibodies or T helper cells or both were responsible for
the observed enhanced disease symptoms.
In conclusion, we developed “all-in-one” inﬂuenza virosomes,
with MPLA and DOGS-NTA-Ni incorporated in the membrane
and NP protein conjugated on the surface. These “all-in-one”
virosomes could activate APCs and enhance the uptake of NP
protein by APCs in vitro and favored the generation of NP-speciﬁc
CD8 T cell responses in vivo. Although virosome-induced NP-
speciﬁcCTLswerenot involved inheterosubtypic cross-protection
in this study, our results provide a basis for the use of MPLA-
adjuvanted inﬂuenza virosomes containing DOGS-NTA-Ni lipid
as platform for a universal inﬂuenza vaccine.Supporting Information
Supporting Information is available from the Wiley Online Library or from
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